KEMRI partners with Roche Diagnostics to strengthen HIV/AIDS response in Kenya.

Kenyan Medical Research Institute (KEMRI) has partnered with
Roche Diagnostics, the Swiss based world’s largest manufacturer of biotech medicines and a
leader in state-of-the-art diagnostics to unveil the second state of the art HIV Viral Load
Testing and monitoring laboratory in Kenya.
The new instrument, the Cobas® 8800, is housed at the KEMRI headquarters in Nairobi, is the
second of its kind in Kenya following the installation of another one at KEMRI’s Centre for
Global Health Research in Kisumu in 2016.
The new laboratory has a capacity to test more than 300,000 Kenyans living with HIV and is
housing Roche Diagnostics’ flagship high throughput system for HIV Viral Load Testing which
helps minimise the amount of time taken to analyse HIV samples in addition to providing more
accurate results.
Through the Public-Private Partnership between KEMRI and Roche Diagnostics, the latter will
also provide training for Kenyan laboratory technicians to operate the new system and provide
sustainable pricing for the HIV Reagents through Roche Diagnostics’ access pricing as part of
the company’s Global Access Program.
“I am really excited to be here in Nairobi at the launch of this important partnership with
KEMRI. As Roche we are proud to be able to help make a difference to the lives of patients with
HIV/AIDS.” said Dr. Severin Schwan.
The UNAIDS 90:90:90 goals target that by 2020, 90 percent of people living with HIV will know
their status, 90 percent of these will receive sustainable antiretroviral treatment and 90 percent
of those on treatment will have sustainable suppression of their virus. According to a report by
Kenya Aids Strategic Framework, counties around the lake region of Nyanza have the highest
number of HIV infections. Roche Diagnostics has been in Kenya for more than 20 years and has
more than 30 permanent employees.